These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 26161698)

  • 21. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
    Susanti NMP; Tjahjono DH
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
    Bose P; Simmons GL; Grant S
    Expert Opin Investig Drugs; 2013 Jun; 22(6):723-38. PubMed ID: 23647051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
    Goel B; Tripathi N; Bhardwaj N; Jain SK
    Curr Top Med Chem; 2020; 20(17):1535-1563. PubMed ID: 32416692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in CDK inhibitors for cancer therapy.
    Heptinstall AB; Adiyasa I; Cano C; Hardcastle IR
    Future Med Chem; 2018 Jun; 10(11):1369-1388. PubMed ID: 29846081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
    Balakrishnan A; Vyas A; Deshpande K; Vyas D
    World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
    McInnes C
    Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting cyclin-dependent kinases in anti-neoplastic therapy.
    Bruyère C; Meijer L
    Curr Opin Cell Biol; 2013 Dec; 25(6):772-9. PubMed ID: 24011867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDK4/6 inhibitors in breast cancer.
    Dukelow T; Kishan D; Khasraw M; Murphy CG
    Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
    Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
    Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of cyclin-dependent kinases - a review of the recent patent literature.
    Basso AD; Doll RJ
    Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):357-67. PubMed ID: 18221046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclin-dependent kinase inhibitors for the treatment of lung cancer.
    Qin A; Reddy HG; Weinberg FD; Kalemkerian GP
    Expert Opin Pharmacother; 2020 Jun; 21(8):941-952. PubMed ID: 32164461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020-present.
    Huang X; Xu S; Duan L; Xu S; Zhu W
    Expert Opin Ther Pat; 2024 Sep; 34(9):825-842. PubMed ID: 39011556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The history and future of targeting cyclin-dependent kinases in cancer therapy.
    Asghar U; Witkiewicz AK; Turner NC; Knudsen ES
    Nat Rev Drug Discov; 2015 Feb; 14(2):130-46. PubMed ID: 25633797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
    Xie Z; Hou S; Yang X; Duan Y; Han J; Wang Q; Liao C
    J Med Chem; 2022 May; 65(9):6356-6389. PubMed ID: 35235745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.
    Pitts TM; Davis SL; Eckhardt SG; Bradshaw-Pierce EL
    Pharmacol Ther; 2014 May; 142(2):258-69. PubMed ID: 24362082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy.
    Wang YT; Jiang SQ; Zhang SL
    Molecules; 2024 Jun; 29(13):. PubMed ID: 38998978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances on CDK inhibitors: An insight by means of in silico methods.
    Tutone M; Almerico AM
    Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticancer therapeutic strategies based on CDK inhibitors.
    Esposito L; Indovina P; Magnotti F; Conti D; Giordano A
    Curr Pharm Des; 2013; 19(30):5327-32. PubMed ID: 23394082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.
    Liang H; Du J; Elhassan RM; Hou X; Fang H
    Expert Opin Investig Drugs; 2021 Jan; 30(1):61-76. PubMed ID: 33183110
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.